About Enliven

Enliven Therapeutics, Inc., incorporated in Delaware in June 2019, is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule inhibitors aimed at helping cancer patients not only live longer but also live better. The company’s mission is to improve survival rates and enhance overall patient well-being by addressing both existing and emerging unmet needs through a precision oncology approach. Enliven’s discovery process integrates deeply validated biological targets with differentiated chemistry, all aimed at designing best-in-class or first-in-class therapies. By combining clinically validated targets and targeted product profiles (TPPs) with rigorous clinical trial designs and regulatory strategies, Enliven strives to develop drug candidates with a higher likelihood of clinical and commercial success. Clinically validated targets refer to biological targets demonstrated to achieve statistically significant efficacy endpoints in published third-party clinical trials, which Enliven leverages to increase the probability of success in developing its candidates. The company has assembled a team of seasoned drug hunters with extensive expertise in discovering and developing small molecule kinase inhibitors. This team includes over 20 principal or co-inventors of candidates that have advanced into clinical trials, including four FDA-approved products: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib), and Retevmo (selpercatinib). Company Website: http://www.imaratx.com Address: 6200 Lookout Road Boulder, CO 80301